

BRAND OF STANDARD RELEASE TACROLIMUS

From August 1^{st} 2018, the transplant unit in Edinburgh started to use twice daily Adoport as an alternative to Prograf for **NEW** transplant patients.



EXISTING transplant patients will continue to be prescribed twice daily Prograf.



There are no plans currently to use an alternative long acting tacrolimus product – patients prescribed Advagraf should continue to be prescribed Advagraf.

Inadvertent switching between oral tacrolimus products has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, **ORAL TACROLIMUS**PRODUCTS SHOULD BE PRESCRIBED, DISPENSED AND ADMINISTERED BY BRAND NAME ONLY (as per MHRA advice June 2012).

Written by: Linda Bell – Renal Pharmacist Date: September 2021, review date September 2022